GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹788 Cr | ₹800 Cr | ₹1,063 Cr | ₹337 Cr | ₹361 Cr |
What is the latest Contingent Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹788 Cr |
| Mar2025 | ₹800 Cr |
| Mar2024 | ₹1,063 Cr |
| Mar2023 | ₹337 Cr |
| Mar2022 | ₹361 Cr |
How is Contingent Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹788 Cr | -1.56 | |
| Mar2025 | ₹800 Cr | -24.74 | |
| Mar2024 | ₹1,063 Cr | 215.81 | |
| Mar2023 | ₹337 Cr | -6.81 | |
| Mar2022 | ₹361 Cr | - | |
Compare Contingent Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹71,041.0 Cr | 5.5% | 14.9% | 26.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹460,696.0 Cr | 0.5% | -4% | 15.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,063.0 Cr | 9.1% | 18.2% | 47.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,515.0 Cr | 3.6% | 3.4% | 36.4% | Stock Analytics | |
| CIPLA | ₹114,554.0 Cr | -1.2% | -3.3% | -10.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,308.6 Cr | -1.4% | 2.9% | -8% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 5.5% |
14.9% |
26.8% |
| SENSEX | -0.4% |
-0.5% |
-5.8% |
You may also like the below Video Courses